Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00005056
Status:
COMPLETED
Last Update Posted:
2013-06-26
First Post:
2000-04-06
Brief Title:
Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
Sponsor:
Cancer Research UK
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of Bryostatin-1 in Hypernephroma
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer
PURPOSE Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer
Detailed Description:
OBJECTIVES I Determine the response rates in patients with progressive hypernephroma treated with bryostatin 1 II Determine the toxicity of this regimen in these patients
OUTLINE This is a multicenter study Patients receive bryostatin 1 IV over 24 hours on days 1 8 and 15 Treatment repeats every 4 weeks for 2 courses For patients with stable or responding disease after completion of course 2 treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study within 12-18 months
OUTLINE This is a multicenter study Patients receive bryostatin 1 IV over 24 hours on days 1 8 and 15 Treatment repeats every 4 weeks for 2 courses For patients with stable or responding disease after completion of course 2 treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study within 12-18 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067651 | REGISTRY | None | None |
| EU-20001 | None | None | None |
| NCI-T95-0024 | Registry Identifier | PDQ Physician Data Query | None |